Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPT-3: KarXT in Psychosis Associated With Alzheimer's Disease
NCT05980949Phase 3Recruiting
- Sponsor
- Karuna Therapeutics
- Start
- Jul 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of xanomeline in psychosis, sponsored by Karuna Therapeutics. Started Jul 2023; status: recruiting.
02
Drugs
xanomeline
03
Conditions
psychosis
Beyond the preview
Go deeper on NCT05980949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05980949.